Boehringer Ingelheim Kg v Johnson and Johnson

Boehringer Ingelheim KG (the applicant) sought to revoke a patent held by Johnson & Johnson (the respondent) concerning a novel method for treating inflammatory bowel disease. The applicant contended that the patent was invalid on several grounds, including lack of novelty, obviousness, and insufficient disclosure. The dispute centred on whether the claimed method, which involved administering a specific antibody, was sufficiently distinct from prior art and whether the patent adequately described how to implement the invention. The matter came before the Federal Court of Australia.

The primary legal issues before the Court were whether the patent for the method of treating inflammatory bowel disease was valid. Specifically, the Court had to determine if the claimed invention possessed the requisite novelty and inventive step, and if the patent specification provided an adequate description of the invention, enabling a person skilled in the art to perform it. The applicant also raised arguments concerning the scope of the claims and whether they were supported by the disclosure in the specification.

In its reasoning, the Court analysed the prior art in detail, comparing it with the claims of the respondent's patent. The Court applied the principles of patent law concerning novelty and inventive step, considering whether the claimed method was obvious to a person skilled in the art at the priority date of the patent, having regard to the existing knowledge. The Court also examined the sufficiency of the disclosure, assessing whether the specification provided enough information to enable the skilled person to carry out the invention without undue burden or further invention. The Court found that the patent specification did not adequately describe the invention and that the claims were not supported by the disclosure.

Consequently, the Court ordered that the patent be revoked.